Review





Similar Products

94
Bioss antibodies hif 1α bs 20399r
Antibodies Hif 1α Bs 20399r, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies hif 1α bs 20399r/product/Bioss
Average 94 stars, based on 1 article reviews
antibodies hif 1α bs 20399r - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

94
Bioss antibody hif 1α bs 20399r
Antibody Hif 1α Bs 20399r, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody hif 1α bs 20399r/product/Bioss
Average 94 stars, based on 1 article reviews
antibody hif 1α bs 20399r - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

93
Proteintech vegf
Effects of different concentrations of DO on the content of <t>VEGF</t> (A) and MMP‐9 (B) in the skin tissue of mice after incision injury. # p < 0.05, ### p < 0.001 vs. BC group; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. NC group.
Vegf, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vegf/product/Proteintech
Average 93 stars, based on 1 article reviews
vegf - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

90
Proteintech vegf-α antibody
Effects of <t>DQJD‐mediated</t> <t>RXR‐γ/PPAR‐γ/VEGF‐α</t> activation in CCH‐induced rats. (A) Representative immunoblots of cortical RXR‐γ, VEGF‐α and PPAR‐γ. GAPDH was used as a control reference protein. (B–D) Data were expressed as a multiple of the density change compared to the control tissue by Image J software (mean ± SD, n = 5), **** p < 0.0001 (versus control); # p < 0.05 (versus model); ## p < 0.01 (versus model); ### p < 0.001 (versus model). PPAR‐γ, Peroxisome proliferator‐activated receptor gamma; RXR‐γ, Retinoid × receptor gamma; VEGF‐α, Vascular endothelial growth factor α.
Vegf α Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vegf-α antibody/product/Proteintech
Average 90 stars, based on 1 article reviews
vegf-α antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
ELK Biotechnology mouse vegfα elisa kit
An AAV.CPP.16-mediated gene therapy for idiopathic pulmonary fibrosis (A) Schematic diagram illustrating design of a bifunctional fusion protein that inhibits VEGF and TGF-β1 and construction of an AAV vector expressing such a protein. (B) Experimental design for testing the AAV.CPP.16 gene therapy (CPP.16-IPF trap) in a bleomycin-induced IPF mouse model. i.t., intratracheal; inhal., Inhaled; i.g., intragastric. (C) Representative H&E staining on lung sections in mice with different treatments. Scale bar: 200 μm for low-magnification images and 50 μm for enlarged images. (D) Quantification of lung cell areas in H&E-stained lung sections. n = 3–6 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (E) Representative Masson, picrosirius red, and αSMA immunohistochemical staining of lung sections in mice with different treatments. Masson (blue) and picrosirius red (red) stainings label collagen expression. Scale bar: 200 μm. (F) Quantification of fibrotic areas on lung sections. n = 3–6 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. PBS, phosphate-buffered saline; BLM, bleomycin; IPF, idiopathic pulmonary fibrosis; PFD, pirfenidone; H&E, hematoxylin and eosin.
Mouse Vegfα Elisa Kit, supplied by ELK Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse vegfα elisa kit/product/ELK Biotechnology
Average 90 stars, based on 1 article reviews
mouse vegfα elisa kit - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

96
Proteintech antivegf α
An AAV.CPP.16-mediated gene therapy for idiopathic pulmonary fibrosis (A) Schematic diagram illustrating design of a bifunctional fusion protein that inhibits VEGF and TGF-β1 and construction of an AAV vector expressing such a protein. (B) Experimental design for testing the AAV.CPP.16 gene therapy (CPP.16-IPF trap) in a bleomycin-induced IPF mouse model. i.t., intratracheal; inhal., Inhaled; i.g., intragastric. (C) Representative H&E staining on lung sections in mice with different treatments. Scale bar: 200 μm for low-magnification images and 50 μm for enlarged images. (D) Quantification of lung cell areas in H&E-stained lung sections. n = 3–6 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (E) Representative Masson, picrosirius red, and αSMA immunohistochemical staining of lung sections in mice with different treatments. Masson (blue) and picrosirius red (red) stainings label collagen expression. Scale bar: 200 μm. (F) Quantification of fibrotic areas on lung sections. n = 3–6 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. PBS, phosphate-buffered saline; BLM, bleomycin; IPF, idiopathic pulmonary fibrosis; PFD, pirfenidone; H&E, hematoxylin and eosin.
Antivegf α, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antivegf α/product/Proteintech
Average 96 stars, based on 1 article reviews
antivegf α - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

96
Proteintech anti vegf α
An AAV.CPP.16-mediated gene therapy for idiopathic pulmonary fibrosis (A) Schematic diagram illustrating design of a bifunctional fusion protein that inhibits VEGF and TGF-β1 and construction of an AAV vector expressing such a protein. (B) Experimental design for testing the AAV.CPP.16 gene therapy (CPP.16-IPF trap) in a bleomycin-induced IPF mouse model. i.t., intratracheal; inhal., Inhaled; i.g., intragastric. (C) Representative H&E staining on lung sections in mice with different treatments. Scale bar: 200 μm for low-magnification images and 50 μm for enlarged images. (D) Quantification of lung cell areas in H&E-stained lung sections. n = 3–6 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (E) Representative Masson, picrosirius red, and αSMA immunohistochemical staining of lung sections in mice with different treatments. Masson (blue) and picrosirius red (red) stainings label collagen expression. Scale bar: 200 μm. (F) Quantification of fibrotic areas on lung sections. n = 3–6 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. PBS, phosphate-buffered saline; BLM, bleomycin; IPF, idiopathic pulmonary fibrosis; PFD, pirfenidone; H&E, hematoxylin and eosin.
Anti Vegf α, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti vegf α/product/Proteintech
Average 96 stars, based on 1 article reviews
anti vegf α - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

90
Cell Signaling Technology Inc antibodies against (tlr4, nfκ-b, iκbα, il-6, tnf-α, tgf-β1, vegf-a, and pdgfr-β)
An AAV.CPP.16-mediated gene therapy for idiopathic pulmonary fibrosis (A) Schematic diagram illustrating design of a bifunctional fusion protein that inhibits VEGF and TGF-β1 and construction of an AAV vector expressing such a protein. (B) Experimental design for testing the AAV.CPP.16 gene therapy (CPP.16-IPF trap) in a bleomycin-induced IPF mouse model. i.t., intratracheal; inhal., Inhaled; i.g., intragastric. (C) Representative H&E staining on lung sections in mice with different treatments. Scale bar: 200 μm for low-magnification images and 50 μm for enlarged images. (D) Quantification of lung cell areas in H&E-stained lung sections. n = 3–6 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (E) Representative Masson, picrosirius red, and αSMA immunohistochemical staining of lung sections in mice with different treatments. Masson (blue) and picrosirius red (red) stainings label collagen expression. Scale bar: 200 μm. (F) Quantification of fibrotic areas on lung sections. n = 3–6 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. PBS, phosphate-buffered saline; BLM, bleomycin; IPF, idiopathic pulmonary fibrosis; PFD, pirfenidone; H&E, hematoxylin and eosin.
Antibodies Against (Tlr4, Nfκ B, Iκbα, Il 6, Tnf α, Tgf β1, Vegf A, And Pdgfr β), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against (tlr4, nfκ-b, iκbα, il-6, tnf-α, tgf-β1, vegf-a, and pdgfr-β)/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
antibodies against (tlr4, nfκ-b, iκbα, il-6, tnf-α, tgf-β1, vegf-a, and pdgfr-β) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

96
Proteintech vegf α antibody
An AAV.CPP.16-mediated gene therapy for idiopathic pulmonary fibrosis (A) Schematic diagram illustrating design of a bifunctional fusion protein that inhibits VEGF and TGF-β1 and construction of an AAV vector expressing such a protein. (B) Experimental design for testing the AAV.CPP.16 gene therapy (CPP.16-IPF trap) in a bleomycin-induced IPF mouse model. i.t., intratracheal; inhal., Inhaled; i.g., intragastric. (C) Representative H&E staining on lung sections in mice with different treatments. Scale bar: 200 μm for low-magnification images and 50 μm for enlarged images. (D) Quantification of lung cell areas in H&E-stained lung sections. n = 3–6 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (E) Representative Masson, picrosirius red, and αSMA immunohistochemical staining of lung sections in mice with different treatments. Masson (blue) and picrosirius red (red) stainings label collagen expression. Scale bar: 200 μm. (F) Quantification of fibrotic areas on lung sections. n = 3–6 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. PBS, phosphate-buffered saline; BLM, bleomycin; IPF, idiopathic pulmonary fibrosis; PFD, pirfenidone; H&E, hematoxylin and eosin.
Vegf α Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vegf α antibody/product/Proteintech
Average 96 stars, based on 1 article reviews
vegf α antibody - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

Image Search Results


Effects of different concentrations of DO on the content of VEGF (A) and MMP‐9 (B) in the skin tissue of mice after incision injury. # p < 0.05, ### p < 0.001 vs. BC group; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. NC group.

Journal: Journal of Cosmetic Dermatology

Article Title: Protective Effects of Exogenous Donkey Oil on Skin Healing Under Incisional Wound Damage

doi: 10.1111/jocd.70550

Figure Lengend Snippet: Effects of different concentrations of DO on the content of VEGF (A) and MMP‐9 (B) in the skin tissue of mice after incision injury. # p < 0.05, ### p < 0.001 vs. BC group; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. NC group.

Article Snippet: The ELISA kits IL‐1α and VEGF were purchased from ProteinTech (Wuhan, China, Cat No: KE10024 and KE10009); IL‐6 from Multi Sciences (Hangzhou, China, Cat No: EK206/3‐96); PGE2 from Lanpaibio (Shanghai, China, Cat No: LP‐M05161); MMP‐9 from CUSABIO (Wuhan, China, Cat No: CSB‐E08007m).

Techniques:

Effects of DQJD‐mediated RXR‐γ/PPAR‐γ/VEGF‐α activation in CCH‐induced rats. (A) Representative immunoblots of cortical RXR‐γ, VEGF‐α and PPAR‐γ. GAPDH was used as a control reference protein. (B–D) Data were expressed as a multiple of the density change compared to the control tissue by Image J software (mean ± SD, n = 5), **** p < 0.0001 (versus control); # p < 0.05 (versus model); ## p < 0.01 (versus model); ### p < 0.001 (versus model). PPAR‐γ, Peroxisome proliferator‐activated receptor gamma; RXR‐γ, Retinoid × receptor gamma; VEGF‐α, Vascular endothelial growth factor α.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Daqinjiao Decoction Ameliorates CSVD via RXR‐γ/PPAR‐γ/VEGF‐α Pathway: Insights From Transcriptome Sequencing and Network Pharmacology

doi: 10.1111/jcmm.70712

Figure Lengend Snippet: Effects of DQJD‐mediated RXR‐γ/PPAR‐γ/VEGF‐α activation in CCH‐induced rats. (A) Representative immunoblots of cortical RXR‐γ, VEGF‐α and PPAR‐γ. GAPDH was used as a control reference protein. (B–D) Data were expressed as a multiple of the density change compared to the control tissue by Image J software (mean ± SD, n = 5), **** p < 0.0001 (versus control); # p < 0.05 (versus model); ## p < 0.01 (versus model); ### p < 0.001 (versus model). PPAR‐γ, Peroxisome proliferator‐activated receptor gamma; RXR‐γ, Retinoid × receptor gamma; VEGF‐α, Vascular endothelial growth factor α.

Article Snippet: The membrane was incubated with blocking buffer for 5 min at room temperature and washed by adding the configured antibodies, VEGF‐α (1:1000, Proteintech), RXR‐γ (1:800, Proteintech) and PPAR‐γ (1:5000, Proteintech), incubated for 90 min at room temperature and washed for 10 min. ECL chemiluminescence (Solarbio, Beijing, China) was used to develop the bands.

Techniques: Activation Assay, Western Blot, Control, Software

The possible mechanism of DQJD on CSVD. DQJD has beneficial effects on improving inflammation and pathological damage in the cortex and hippocampus in the CSVD model. The mechanism of action may be related to the activation of the RXR‐γ/PPAR‐γ/VEGF signalling pathway.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Daqinjiao Decoction Ameliorates CSVD via RXR‐γ/PPAR‐γ/VEGF‐α Pathway: Insights From Transcriptome Sequencing and Network Pharmacology

doi: 10.1111/jcmm.70712

Figure Lengend Snippet: The possible mechanism of DQJD on CSVD. DQJD has beneficial effects on improving inflammation and pathological damage in the cortex and hippocampus in the CSVD model. The mechanism of action may be related to the activation of the RXR‐γ/PPAR‐γ/VEGF signalling pathway.

Article Snippet: The membrane was incubated with blocking buffer for 5 min at room temperature and washed by adding the configured antibodies, VEGF‐α (1:1000, Proteintech), RXR‐γ (1:800, Proteintech) and PPAR‐γ (1:5000, Proteintech), incubated for 90 min at room temperature and washed for 10 min. ECL chemiluminescence (Solarbio, Beijing, China) was used to develop the bands.

Techniques: Activation Assay

An AAV.CPP.16-mediated gene therapy for idiopathic pulmonary fibrosis (A) Schematic diagram illustrating design of a bifunctional fusion protein that inhibits VEGF and TGF-β1 and construction of an AAV vector expressing such a protein. (B) Experimental design for testing the AAV.CPP.16 gene therapy (CPP.16-IPF trap) in a bleomycin-induced IPF mouse model. i.t., intratracheal; inhal., Inhaled; i.g., intragastric. (C) Representative H&E staining on lung sections in mice with different treatments. Scale bar: 200 μm for low-magnification images and 50 μm for enlarged images. (D) Quantification of lung cell areas in H&E-stained lung sections. n = 3–6 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (E) Representative Masson, picrosirius red, and αSMA immunohistochemical staining of lung sections in mice with different treatments. Masson (blue) and picrosirius red (red) stainings label collagen expression. Scale bar: 200 μm. (F) Quantification of fibrotic areas on lung sections. n = 3–6 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. PBS, phosphate-buffered saline; BLM, bleomycin; IPF, idiopathic pulmonary fibrosis; PFD, pirfenidone; H&E, hematoxylin and eosin.

Journal: Cell Reports Medicine

Article Title: Cross-species tropism of AAV.CPP.16 in the respiratory tract and its gene therapies against pulmonary fibrosis and viral infection

doi: 10.1016/j.xcrm.2025.102144

Figure Lengend Snippet: An AAV.CPP.16-mediated gene therapy for idiopathic pulmonary fibrosis (A) Schematic diagram illustrating design of a bifunctional fusion protein that inhibits VEGF and TGF-β1 and construction of an AAV vector expressing such a protein. (B) Experimental design for testing the AAV.CPP.16 gene therapy (CPP.16-IPF trap) in a bleomycin-induced IPF mouse model. i.t., intratracheal; inhal., Inhaled; i.g., intragastric. (C) Representative H&E staining on lung sections in mice with different treatments. Scale bar: 200 μm for low-magnification images and 50 μm for enlarged images. (D) Quantification of lung cell areas in H&E-stained lung sections. n = 3–6 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (E) Representative Masson, picrosirius red, and αSMA immunohistochemical staining of lung sections in mice with different treatments. Masson (blue) and picrosirius red (red) stainings label collagen expression. Scale bar: 200 μm. (F) Quantification of fibrotic areas on lung sections. n = 3–6 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. PBS, phosphate-buffered saline; BLM, bleomycin; IPF, idiopathic pulmonary fibrosis; PFD, pirfenidone; H&E, hematoxylin and eosin.

Article Snippet: Mouse TGFβ1 ELISA Kit , ELK Biotechnology , Cat# ELK1186.

Techniques: Plasmid Preparation, Expressing, Staining, Immunohistochemical staining, Saline

Inhibition of VEGF and TGF-β1 pathways in the mouse lung treated with AAV.CPP.16-IPF trap gene therapy (A) Transgene expression in the mouse lung treated with AAV.CPP.16-IPF trap. Reverse-transcription PCR (RT-PCR) was performed using primers that targeted the two fragments of the fusion protein. n = 4 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (B) Concentration of VEGFα in the mouse serum measured by ELISA. n = 3–8 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (C) Concentration of TGF-β1 in the mouse serum measured by ELISA. n = 3–8 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (D) mRNA expression levels of fibrogenic genes Acta2 , Postn , and Fn in the lung tissues. n = 4 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (E) mRNA expression levels of inflammation genes Tnfa , Il6 , and Il1b in the lung tissues. n = 4 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (F–H) Immunoblot quantification of key fibrogenic and inflammation proteins. n = 3 per group. mean ± SEM, one-way ANOVA with Tukey’s post-test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. PBS, phosphate-buffered saline; BLM, bleomycin; IPF, idiopathic pulmonary fibrosis; PFD, pirfenidone.

Journal: Cell Reports Medicine

Article Title: Cross-species tropism of AAV.CPP.16 in the respiratory tract and its gene therapies against pulmonary fibrosis and viral infection

doi: 10.1016/j.xcrm.2025.102144

Figure Lengend Snippet: Inhibition of VEGF and TGF-β1 pathways in the mouse lung treated with AAV.CPP.16-IPF trap gene therapy (A) Transgene expression in the mouse lung treated with AAV.CPP.16-IPF trap. Reverse-transcription PCR (RT-PCR) was performed using primers that targeted the two fragments of the fusion protein. n = 4 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (B) Concentration of VEGFα in the mouse serum measured by ELISA. n = 3–8 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (C) Concentration of TGF-β1 in the mouse serum measured by ELISA. n = 3–8 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (D) mRNA expression levels of fibrogenic genes Acta2 , Postn , and Fn in the lung tissues. n = 4 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (E) mRNA expression levels of inflammation genes Tnfa , Il6 , and Il1b in the lung tissues. n = 4 per group, mean ± SEM, one-way ANOVA with Tukey’s post-test. (F–H) Immunoblot quantification of key fibrogenic and inflammation proteins. n = 3 per group. mean ± SEM, one-way ANOVA with Tukey’s post-test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. PBS, phosphate-buffered saline; BLM, bleomycin; IPF, idiopathic pulmonary fibrosis; PFD, pirfenidone.

Article Snippet: Mouse TGFβ1 ELISA Kit , ELK Biotechnology , Cat# ELK1186.

Techniques: Inhibition, Expressing, Reverse Transcription, Reverse Transcription Polymerase Chain Reaction, Concentration Assay, Enzyme-linked Immunosorbent Assay, Western Blot, Saline